]>

  CeNeS announces additional data on M6G to be presented at leading
                          pain conferences

Cambridge, UK, 1 September 2003 - CeNeS Pharmaceuticals plc (LSE:
CEN) today announced that additional data will be presented in the
next two months on the potential of M6G (morphine-6-glucuronide) for
the treatment of post-operative pain at three major European and
North American pain conferences. M6G is currently in phase III of its
clinical development for the treatment of post-operative pain.

The conferences are:-

  * 2nd September  - 4th Congress of the European Federation of the
    International Association of the Study of Pain Chapters - Prague,
    Czech Republic;
  * 10th October - International Pain Research/Euro Pain Meeting -
    King's College, London;
  * 11th October - American Society if Anesthesiologists Annual
    Meeting- San Francisco, USA

Further details will be announced in due course.

This news release contains forward-looking statements that reflect
the Company's current expectation regarding future events.
Forward-looking statements involve risks and uncertainties. Actual
events could differ materially from those projected herein and depend
on a number of factors including the success of the Company's
research strategy, the applicability of the discoveries made therein,
the successful and timely completion of clinical studies and the
uncertainties related to the regulatory process.

For more information please contact:


CeNeS Pharmaceuticals plc Euro RSCG Life NRP
Alan Goodman              Dr Douglas Pretsell
Neil Clark                Tel: +44 (0)20 7726 4452
Tel: +44 (0)1223 266466   Fax: +44 (0)20 7726 4453
Fax: +44 (0)1223 266467





Notes to Editors:

CeNeS is a biopharmaceutical company specialising in the development
and commercialisation of drugs for pain control. The company has
development assets targeting pain and has a portfolio of carried
interests in assets that it has divested. The company is based in
Cambridge, England. For further information visit www.cenes.co.uk.

M6G
M6G, a natural metabolite of morphine, is in development by CeNeS for
the treatment of moderate to severe pain. Morphine is a highly
effective analgesic that has been used for many years despite the
unpleasant side effects of nausea and vomiting and the potential
dangers of respiratory depression.

M6G has undergone several Phase II clinical trials with more than 450
patients receiving the compound. The most recent Phase II trials were
designed to establish the analgesic effects of different doses of M6G
administered at different times compared to a standard morphine
treatment regime. Phase III efficacy studies are currently being
undertaken: a pivotal, dose-ranging placebo controlled study is
scheduled to commence as a multi-centre study in Europe in 2003 in
patients undergoing knee replacement surgery with spinal anaesthesia.
It is planned that this will be followed by a second Phase III trial
in Europe comparing M6G and morphine treatment in patients with
postoperative pain following gastrointestinal and gynaecological
surgery. Side-effect profiles of M6G will be investigated in both
studies. If these trials are successful then M6G will be on target to
be launched in Europe in 2006.

Opiate Analgesia
Analgesia is the process of pain-relief and any pain-relieving drug
is called an analgesic. The most potent known class of analgesics are
the opiates, derived from the opium poppy, which confer a high degree
of pain-relief for severe pain. Opiates, like morphine and codeine,
act centrally in the brain in an area called the periaqueductal grey
area where they mimic the actions of neuromodulators called
endogenous opiates and 'switch off' the sensation of pain centrally.

The markets for M6G
M6G has potential as an analgesic for two types of pain,
post-operative pain and chronic pain, both of which are currently
treated with morphine.



- ---END OF MESSAGE---
Copyright © Hugin ASA 2003. All rights reserved.-----BEGIN PGP SIGNATURE-----
Version: PGP 6.5.8

iQA/AwUBP1Lgou6RaHz0nSHVEQKu3QCcDz5VasIrGJsZPmLOTu/ON9YfI9wAoOaV
lCx899e6C/MiVgR7YCxwE4li
=E0Yz
-----END PGP SIGNATURE-----